YIN QI
With over two decades of experience in clinical development, translational medicine, and regulatory strategy, Yin Qi has held leadership roles at top-tier organizations, including Asymchem and Novartis Institute for Biomedical Research (NIBR). Currently serving as Chief Strategy Officer/Chief Development Officer and Head of U.S. at Asymchem Clinical, he drives strategic initiatives to enhance the company’s CRO capabilities, building early development functions (Translational Medicine, Biomarker Development, PK/PD, and Clinical Research) and establishing U.S.-based regulatory and operational teams. He also lead cross-functional committees, fostered strategic partnerships with global CROs, and ensured regulatory compliance in multi-regional clinical trials.
During his tenure at Novartis (2004–2022), Yin Qi held multiple leadership roles, including Translational Medicine Strategy and Planning Director, where he shaped early development strategies in Asia, optimized resource allocation, and strengthened collaboration between China and Japan. As Early Development Regulatory Director, he led regulatory submissions (IND/CTA), engaged with global health authorities including FDA, BfArm, MHRA, and guided R&D programs in Neurosciences, CV&M, and Respiratory diseases. Earlier, as Clinical Science Therapeutic Area Head (CV&M, Infectious Diseases), he served on boards such as The Disease Area Decision Board and The Protocol Review Committee, overseeing clinical portfolios from development candidate selection to clinical proof of concept, managing multi-million-dollar budgets, and ensuring operational excellence in study design and execution.
Beginning his career in China, Yin Qi held key roles at Novartis China and Beijing Hospital, building clinical research capabilities across APAC, managing pharmacokinetic studies, and engaging with health authorities. Yin Qi’s academic background includes a B.S. in Pharmaceutical Science, an M.S. in Pharmacology, and executive leadership training programs from IMD and CEIBS. His expertise spans clinical development, regulatory strategy, and cross-functional leadership in global drug development
